Aspects of hereditary angioedema genotyping in the era of NGS: The case of F12 gene

• Authors: Sofia Vatsiou , Maria Zamanakou , Gedeon Loules , Teresa González-Quevedo , Grzegorz Porębski , Aldona Juchacz , Maria Bova , Chiara Suffritti , Davide Firinu , Dorottya Csuka , Emmanouil Manousakis , Anna Valerieva , Maria Staevska , Markus Magerl , Henriette Farkas , Anastasios E. Germenis

Title variants

PL

Wybrane aspekty genotypowania wrodzonego obrzęku naczynioruchowego w erze NGS: gen F12

• Languages of publication: EN PL

Abstracts

EN

Objective. To screen a cohort of patients diagnosed with non-FXII angioedema for carriage of variants of F12 gene. Material and methods. DNA samples from 191 patients suffering from primary angioedema with normal C1-INH, 54 samples from non- -affected family members, and 161 samples from C1-INH-HAE (154 type I, 7 type II) patients were included in the study. The F12 gene was genotyped by targeted NGS (100% coverage of translated regions). Sanger sequencing was performed for the verification of all identified variants and family segregation studies. Results. The pathogenic F12 variant c.983C>A was detected in three patients from two unrelated families initially diagnosed as U-HAE. Six additional mutations were identified, four of which were characterized as benign (c.41T>C, c.418C>G, c.1025C>T, c.530C>T) and two of uncertain significance (c.1530G>C, c.1768T>G). Two synonymous variants (c.756C>T and c.711C>T), the common polymorphism c.619G>C, and the functional polymorphism c.-4T>C were detected in allele frequencies similar to those presented in the ExAC database for the European population. One more not yet reported synonymous variant (c. 1599A>G) was also found. Conclusion. Analyzing the entire translated region of F12 gene is important in order to identify new variants that possibly affect HAE expressivity. Interestingly, genetic analysis of F12 supports not only the diagnosis of FXII-HAE but also the correct exclusion diagnosis of U-HAE.

PL

Cel. Przesiewowe badanie kohorty pacjentów z rozpoznanym obrzę- kiem naczynioruchowym innym niż zależny od FXII w kierunku nosicielstwa wariantów genu F12. Materiał i metody. Do badania włączono próbki DNA 191 pacjentów cierpiących na pierwotny obrzęk naczynioruchowy z prawidłowym C1-INH, 54 zdrowych członków rodzin oraz 161 pacjentów z C1-INH-HAE (154 typ I, 7 typ II). Gen F12 był genotypowany metodą NGS (obejmującą cały rejon poddany translacji). Sekwencjonowanie metodą Sangera zostało wykonane celem weryfikacji wszystkich zidentyfikowanych wariantów i badań segregacyjnych rodzin. Wyniki. U trzech pacjentów z dwóch niespokrewnionych rodzin pierwotnie zdiagnozowanych jako U-HAE wykryto patogenny wariant F12: c.983C>A. Zidentyfikowano sześć dodatkowych mutacji, z których cztery zostały określone jako łagodne (c.41T>C, c.418C>G, c.1025C>T, c.530C>T), a dwie jako mutacje o niepewnym znaczeniu (c.1530G>C, c.1768T>G). Stwierdzono dwa warianty synonimiczne (c.756C>T oraz c.711C>T), pospolity polimorfizm (c.619G>C) oraz czynnościowy polimorfizm c.-4T>C z częstością alleliczną podobną do podawanej w bazie ExAC dla populacji europejskiej. Wykryto również jeden nie raportowany dotychczas wariant synonimiczny (c. 1599A>G). Wnioski. Analiza całego rejonu genu F12 poddawanego translacji jest ważna dla identyfikowania nowych wariantów, które mogą oddziaływać na ekspresję HAE. Ponadto, analiza genetyczna F12 pozwala nie tylko na potwierdzenie rozpoznania FXII-HAE, ale również prawidłowe wykluczenie rozpoznania U-HAE.

Keywords

EN

F12 gene; F12 mutations; hereditary angioedema; next-generationsequencing

Discipline

• MEDICINE: MEDICINE

• Publisher: Oficyna Wydawnicza Mediton
• Journal: Alergia Astma Immunologia - przegląd kliniczny
• Year: 2018
• Volume: 23
• Issue: 4
• Pages: 205-210

Contributors

author

Sofia Vatsiou

• CeMIA SA, Larissa, Greece, Department of Immunology & Histocompatibility, University of Thessaly, School of Health Sciences, Faculty of Medicine, Larissa, Greece

author

Maria Zamanakou

• CeMIA SA, Larissa, Greece

author

Gedeon Loules

• CeMIA SA, Larissa, Greece

author

Teresa González-Quevedo

• Reference Unit for Angioedema in Andalusia, Allergy Department, Hospital Universitario Virgen del Rocio, Seville, Spain

author

Grzegorz Porębski

• Department of Clinical and Environmental Allergology, Jagiellonian University Medical College, Krakow, Poland

author

Aldona Juchacz

• Centre of Pulmonology and Thoracic Surgery, Poznan, Poland

author

Maria Bova

• Department of Translational Medicine, University Federico II, Naples, Italy

author

Chiara Suffritti

• Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy

author

Davide Firinu

author

Dorottya Csuka

• Hungarian Angioedema Reference Center, 3rd Department of Internal Medicine, Semmelweis University, Budapest, Hungary

author

Emmanouil Manousakis

• Allergy Department, 2nd Pediatric Clinic, University of Athens, Athens, Greece

author

Anna Valerieva

• Clinical Centre of Allergology, Medical University, Sofia, Bulgaria

author

Maria Staevska

• Clinical Centre of Allergology, Medical University, Sofia, Bulgaria

author

Markus Magerl

• Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Germany

author

Henriette Farkas

• Hungarian Angioedema Reference Center, 3rd Department of Internal Medicine, Semmelweis University, Budapest, Hungary

author

Anastasios E. Germenis

• CeMIA SA, Larissa, Greece, Department of Immunology & Histocompatibility, University of Thessaly, School of Health Sciences, Faculty of Medicine, Larissa, Greece

References

• 1. Cicardi M, Aberer W, Banerji A, et al. Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. Allergy 2014; 69: 602-16.
• 2. Dewald G. A missense mutation in the plasminogen gene, within the plasminogen kringle 3 domain, in hereditary angioedema with normal C1 inhibitor. Biochem Biophys Res Commun 2018; 498: 193-8.
• 3. Bork K, Wulff K, Steinmüller-Magin L, et al. Hereditary angioedema with a mutation in the plasminogen gene. Allergy 2018; 73: 442- 50.
• 4. Bafunno V, Firinu D, D'Apolito M, et al. Mutation of the angio-poietin-1 gene (ANGPT1) associates with a new type of hereditary angioedema. J Allergy Clin Immunol 2018; 141: 1009-17.
• 5. Loules G, Zamanakou M, Parsopoulou F, et al. Targeted next-generation sequencing for the molecular diagnosis of hereditary angioedema due to C1-inhibitor deficiency. Gene 2018; 667: 76-82.
• 6. Bork K. Hereditary angioedema with normal C1 inhibitor activity including hereditary angioedema with coagulation factor XII gene mutations. Immunol Allergy Clin North Am 2006; 6: 709-24.
• 7. Bork K, Wulff K, Meinke P, et al. A novel mutation in the coagulation factor 12 gene in subjects with hereditary angioedema and normal C1-inhibitor. Clin Immunol 2011; 141: 31-5.
• 8. Kiss N, Barabás E, Várnai K, et al. Novel duplication in the F12 gene in a patient with recurrent angioedema. Clin Immunol 2013; 149: 142-5.
• 9. Speletas M, Szilágyi Á, Csuka D, et al. F12-46C/T polymorphism as modifier of the clinical phenotype of hereditary angioedema. Allergy 2015; 70: 1661-4.
• 10. Charignon D, Ponard D, de Gennes C, et al. SERPING1 and F12 combined variants in a hereditary angioedema family. Ann Allergy Asthma Immunol 2018; 121: 500-2.
• 11. Singhamatr P, Kanjanapongkul S, Rojnuckarin P. Molecular analysis of factor XII gene in Thai patients with factor XII deficiency. Blood Coagul Fibrinolysis 2013; 24: 599-604.
• 12. Dewald G, Bork K. Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. Biochem Biophys Res Commun 2006; 43: 1286-9.
• 13. Cichon S, Martin L, Hennies HC, et al. Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III. Am J Hum Genet 2006; 79: 1098-104.
• 14. Bork K, Kleist R, Hardt J, et al. Kallikrein - kinin system and fibrinolysis in hereditary angioedema due to factor XII gene mutation Thr309Lys. Blood Coagul Fibrinolysis 2009; 20: 325-32.
• 15. Björkqvist J, de Maat S, Lewandrowski U, et al. Defective glycosylation of coagulation factor XII underlies hereditary angioedema type III. J Clin Invest 2015; 125: 3132-46.
• 16. Magerl M, Germenis AE, Maas C, Maurer M. Hereditary Angioedema with Normal C1 Inhibitor: Update on Evaluation and Treatment. Immunol Allergy Clin North Am 2017; 37: 571-84.
• 17. de Maat S, Björkqvist J, Suffritti C, et al. Plasmin is a natural trigger for bradykinin production in patients with hereditary angioedema with factor XII mutations. J Allergy Clin Immunol 2016; 138: 1414- 23.e9.
• 18. Richards S, Aziz N, Bale S, et al. ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015;17: 405-24.
• 19. Caballero T, Canabal J, Rivero Paparoni D, et al. Management of hereditary angioedema in pregnant women: a review. Int J Womens Health 2014; 9: 839-48.
• 20. Miyata T, Kawabata S, Iwanaga S, et al. Coagulation factor XII (Hageman factor) Washington D.C.: inactive factor XIIa results from Cys-571-Ser substitution. Proc Natl Acad Sci U S A 1989; 86: 8319- 22.

• Document Type: article